News Conference News AHA 2024 GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes Michael O'Riordan November 17, 2024
News Conference News AHA 2024 SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity Michael O'Riordan November 16, 2024
News Conference News AHA 2024 Intensive BP Lowering in Diabetes Reduces CV Events: BPROAD Yael L. Maxwell November 16, 2024
News Daily News SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients L.A. McKeown October 23, 2024
News Conference News HFSA 2024 Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity Todd Neale October 01, 2024
News Daily News Medicaid Coverage Improves CV Risk in Some, Post Hoc Analysis Shows Todd Neale September 25, 2024
News Conference News ESC 2024 FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients Michael O'Riordan September 01, 2024
News Conference News ESC 2024 Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery Todd Neale August 30, 2024
News Daily News Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes Michael O'Riordan August 19, 2024
News Daily News Semaglutide Has Similar Benefits in Women and Men With HFpEF Todd Neale June 26, 2024
News Daily News Bariatric Surgery Reduces Hard Events in Obese Patients With Sleep Apnea Michael O'Riordan June 21, 2024
News Daily News Statins Effective For Primary Prevention in Old and Very Old Michael O'Riordan May 29, 2024
News Daily News EMA: No Evidence of Link Between GLP-1 Receptor Agonists and Suicidal Thoughts Todd Neale April 12, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Conference News ACC 2024 STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed L.A. McKeown April 06, 2024
News Daily News Injectable Semaglutide Shortage Forces Physicians to Pivot Todd Neale February 05, 2024
News Daily News Universal Risk Tool Works Well in Both Primary and Secondary Prevention Michael O'Riordan February 01, 2024